Cargando…

Screening of selective histone deacetylase inhibitors by proteochemometric modeling

BACKGROUND: Histone deacetylase (HDAC) is a novel target for the treatment of cancer and it can be classified into three classes, i.e., classes I, II, and IV. The inhibitors selectively targeting individual HDAC have been proved to be the better candidate antitumor drugs. To screen selective HDAC in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Dingfeng, Huang, Qi, Zhang, Yida, Zhang, Qingchen, Liu, Qi, Gao, Jun, Cao, Zhiwei, Zhu, Ruixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542186/ https://www.ncbi.nlm.nih.gov/pubmed/22913517 http://dx.doi.org/10.1186/1471-2105-13-212

Ejemplares similares

Proteochemometric Modeling of the Antigen-Antibody Interaction: New Fingerprints for Antigen, Antibody and Epitope-Paratope Interaction
por: Qiu, Tianyi, et al.
Publicado: (2015)

Finding the molecular scaffold of nuclear receptor inhibitors through high-throughput screening based on proteochemometric modelling
por: Qiu, Tianyi, et al.
Publicado: (2018)

Proteochemometric Modeling of the Bioactivity Spectra of HIV-1 Protease Inhibitors by Introducing Protein-Ligand Interaction Fingerprint
por: Huang, Qi, et al.
Publicado: (2012)

bSiteFinder, an improved protein-binding sites prediction server based on structural alignment: more accurate and less time-consuming
por: Gao, Jun, et al.
Publicado: (2016)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Next-generation of selective histone deacetylase inhibitors
por: Yang, Feifei, et al.
Publicado: (2019)

Virtual screening and experimental validation of novel histone deacetylase inhibitors
por: Huang, Yan-xin, et al.
Publicado: (2016)

The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
por: Cao, Fangyuan, et al.
Publicado: (2018)

SEPPA 2.0—more refined server to predict spatial epitope considering species of immune host and subcellular localization of protein antigen
por: Qi, Tao, et al.
Publicado: (2014)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Prediction of the potency of mammalian cyclooxygenase inhibitors with ensemble proteochemometric modeling
por: Cortes-Ciriano, Isidro, et al.
Publicado: (2015)

Proteochemometric Modeling Identifies Chemically Diverse Norepinephrine Transporter Inhibitors
por: Bongers, Brandon J., et al.
Publicado: (2023)

Unbiased descriptor and parameter selection confirms the potential of proteochemometric modelling
por: Freyhult, Eva, et al.
Publicado: (2005)

Getting a GRP on histone deacetylase inhibitor selectivity
por: Ding, Husheng, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Proteochemometric modeling of HIV protease susceptibility
por: Lapins, Maris, et al.
Publicado: (2008)

Proteochemometric modeling in a Bayesian framework
por: Cortes-Ciriano, Isidro, et al.
Publicado: (2014)

Unsupervised Representation Learning for Proteochemometric Modeling
por: Kim, Paul T., et al.
Publicado: (2021)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

High throughput screening identifies modulators of histone deacetylase inhibitors
por: Gaupel, Ann-Christin, et al.
Publicado: (2014)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach
por: Hsu, Kai-Cheng, et al.
Publicado: (2017)

Zinc binding groups for histone deacetylase inhibitors
por: Zhang, Lei, et al.
Publicado: (2018)

Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives
por: Zhang, Hua, et al.
Publicado: (2015)

Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
por: Tu, Bin, et al.
Publicado: (2020)

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
por: Li, Guo, et al.
Publicado: (2020)

Linking the Resource Description Framework to cheminformatics and proteochemometrics
por: Willighagen, Egon L, et al.
Publicado: (2011)

Computational Design of a Time-Dependent Histone Deacetylase 2 Selective Inhibitor
por: Zhou, Jingwei, et al.
Publicado: (2014)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
por: Sager, Philip T, et al.
Publicado: (2015)

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs
por: Wang, Yuren, et al.
Publicado: (2017)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers
por: Wagner, F. F., et al.
Publicado: (2015)

Histone deacetylase inhibitor screening identifies HC toxin as the most effective in intrahepatic cholangiocarcinoma cells
por: ZHOU, WENJIE, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g49te7s04d6i0pide14lm53u7a